mRNA vaccine technology is a field full of promise – as well as unanswered questions – for communities living with the burden of the world’s most deadly infectious diseases.
Failure to grant a patent waiver under the WTO's TRIPS Agreement has stalled ramping up of production in Africa and other developing countries of coronavirus vaccines.